SOLLICE BIOTECH Revenue and Competitors
Estimated Revenue & Valuation
- SOLLICE BIOTECH's estimated annual revenue is currently $2.3M per year.
- SOLLICE BIOTECH's estimated revenue per employee is $155,000
Employee Data
- SOLLICE BIOTECH has 15 Employees.
- SOLLICE BIOTECH grew their employee count by 0% last year.
SOLLICE BIOTECH's People
| Name | Title | Email/Phone |
|---|
SOLLICE BIOTECH Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $81.4M | 375 | 40% | N/A | N/A |
#2 | $16.9M | 109 | 22% | N/A | N/A |
#3 | $156.1M | 120 | -70% | $145M | N/A |
#4 | $2.9M | 37 | -24% | $150M | N/A |
#5 | $1.3M | 17 | 0% | $459.5M | N/A |
#6 | $49.2M | 254 | 15% | $180.7M | N/A |
#7 | $7M | 45 | -2% | N/A | N/A |
#8 | $256.3M | 840 | 9% | $168.5M | N/A |
#9 | $4.2M | 27 | -7% | N/A | N/A |
#10 | $10.1M | 65 | 5% | N/A | N/A |
What Is SOLLICE BIOTECH?
SOLLICE Biotech is a life sciences key partner, as leading creator, producer and high-quality provider of ACTIVE ingredients to benefit the cosmetics market. SOLLICE Biotech offers a full range of innovative high-performance and functional active ingredients, which are scientifically proven to provide personal care and innovative solutions.
keywords:N/A
N/A
Total Funding
15
Number of Employees
$2.3M
Revenue (est)
0%
Employee Growth %
N/A
Valuation
N/A
Accelerator
SOLLICE BIOTECH News
Sollice Biotech, DSM, Ashland, The Lubrizol Corporation, ELEMENTIS PLC, Eastman Chemical Company, BASF SE, Clariant, Dow, Evonik Industries...
Bio-Based Cosmetics and Personal Care Ingredients Market to Witness Growth Acceleration | Sollice Biotech, DSM, Ashland.
... Chemical Company, ELEMENTIS PLC, Genomatica Inc., Nouryon, Sollice Biotech, Solvay, Lubrizol Corporation and other prominent players.
Other Companies in Toulouse
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $1.1M | 15 | 0% | N/A |
#2 | $1.4M | 16 | -6% | N/A |
#3 | $2.1M | 17 | N/A | N/A |
#4 | $2.7M | 18 | 0% | N/A |
#5 | $2.4M | 18 | -10% | N/A |